UK referendum on Europe: what’s the potential medtech regulatory fallout?
This article was originally published in Clinica
For the last two and a half decades, the careers of EU medtech regulatory experts have orbited around the output of Brussels and its impact at EU, national and even international level. So should those of us in the UK fear the referendum on EU membership, as promised by the newly elected Conservative government? How worried should the UK be – and indeed the rest of Europe – in terms of regulatory stability should the outcome of the vote, expected in 2017, signal an exit from the EU? And what will the impact be on the rest of Europe?
You may also be interested in...
Where are the biggest challenges for notified bodies and manufacturers now there is some experience with the MDR, and can the sector manage the new regulatory requirements successfully?
The European Commission has finally published detailed guidance on the EU IVDR’s classification rules. The IVDR’s completely new classification regime means guidance is urgently needed.
Do you know how to avoid the pitfalls when it comes to clinical evidence under the MDR? Or whether evidence gathered outside the US counts? Amie Smirthwaite of Maetrics answers these and other pivotal questions in this third and final part of an interview series with Medtech Insight.